[SCHEDULE 13G] Silexion Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

The reporting persons—Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton—filed a Schedule 13G reporting beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K122), representing 9.9% of the class. The disclosed position consists of 106,250 ordinary shares and warrants (106,250 Series A-1 and 106,250 Series A-2) subject to conversion limits that cap aggregate beneficial ownership at 224,050 shares to prevent ownership above 9.99%. Lind Global Partners III LLC is the general partner of the fund and Jeff Easton is the managing member; each may be deemed to have sole voting and dispositive power over the reported shares. The filers certify the holdings were not acquired to change or influence control of the issuer.

Insights

Securities Analyst

TL;DR: Routine 13G disclosure showing a 9.9% passive stake limited by warrant anti-dilution/ownership caps.

The filing is a standard passive investor disclosure under Schedule 13G rather than an active Section 13(d) pursuit of control. The ownership mix of shares and exercisable warrants, together with contractual conversion limits keyed to a 9.99% threshold, indicates deliberate structuring to remain below a controlling interest trigger. For investors, this clarifies potential near-term dilution from warrants is contractually constrained and that the reporting parties claim no intent to influence control.

Corporate Governance Expert

TL;DR: Governance impact appears limited; reporting persons assert passive intent and voting/dispositive power is centralized through the fund GP and manager.

The report identifies the governance chain: Lind Global Partners III LLC as general partner and Jeff Easton as managing member, each with sole voting and dispositive power over the shares held by the fund. While a near-10% ownership can be influential, the document contains a certification that shares were not acquired to change control, and the warrant conversion cap further reduces the prospect of an abrupt shift in control. This is a material ownership disclosure but not a notice of control intent or group formation.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Silexion Therapeutics Corp

(Name of Issuer)

Ordinary shares, par value $0.0135 per share

(Title of Class of Securities)

G1281K122

(CUSIP Number)

09/12/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G1281K122

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 224,050.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 224,050.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

224,050.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 106,250 ordinary shares, (ii) 106,250 warrants to purchase ordinary shares (the "Series A-1 Warrants") and (iii) 106,250 warrants to purchase ordinary shares (the "Series A-2 Warrants, together with the Series A-1 Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 224,050 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.

SCHEDULE 13G

CUSIP No. G1281K122

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 224,050.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 224,050.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

224,050.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 106,250 ordinary shares, (ii) 106,250 Series A-1 Warrants and (iii) 106,250 Series A-2 Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 224,050 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.

SCHEDULE 13G

CUSIP No. G1281K122

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 224,050.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 224,050.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

224,050.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 106,250 ordinary shares, (ii) 106,250 Series A-1 Warrants and (iii) 106,250 Series A-2 Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 224,050 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silexion Therapeutics Corp
(b)	Address of issuer's principal executive offices: 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): Lind Global Fund III LP, a Delaware limited partnership; Lind Global Partners III LLC, a Delaware limited liability company; and Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Ordinary shares, par value $0.0135 per share
(e)	CUSIP No.: G1281K122
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	09/18/2025

Lind Global Partners III LLC

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	09/18/2025

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	09/18/2025

FAQ

What stake does Lind Global Fund III LP report in Silexion Therapeutics (SLXNW)?

The filer reports beneficial ownership of 224,050 ordinary shares, representing 9.9% of the class.

How is the 224,050-share position composed?

The position consists of 106,250 ordinary shares plus 106,250 Series A-1 and 106,250 Series A-2 warrants, with conversion limits capping aggregate beneficial ownership at 224,050.

Who may exercise voting or dispositive power over the reported shares?

Lind Global Partners III LLC, as general partner, and Jeff Easton, as managing member, may be deemed to have sole voting and dispositive power over the fund's shares.

Does the filing indicate an intent to influence control of Silexion?

No; the certification states the securities were not acquired and are not held for the purpose of changing or influencing control.

What conversion restriction applies to the warrants?

The warrants contain a provision limiting conversion if doing so would cause the holder to beneficially own more than 9.99% of the company.